Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study

J Am Acad Dermatol. 2020 Mar;82(3):743-746. doi: 10.1016/j.jaad.2019.07.049. Epub 2019 Jul 23.

¹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Harvard Medical School, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
⁵ Harvard Medical School, Boston, Massachusetts; Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
⁶ Harvard Medical School, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
⁷ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: stchen@partners.org.

No abstract available

Publication types